AtriCure CTO Salvatore Privitera sells $546,260 in stock

Investing.com · 2026-11-06 05:46 UTC

AtriCure CTO Salvatore Privitera sells $546,260 in stock

Salvatore Privitera, Chief Technical Officer of AtriCure, Inc. (NASDAQ:ATRC), sold 8,404 shares of common stock on November 4, 2026, according to a recent SEC filing. The transactions totaled $546,260, with shares sold at a price of $65.0 each. The sale comes as AtriCure trades near its 52-week high of $66.02, with the stock delivering a remarkable 95% return over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels—one of 15+ exclusive ProTips available to subscribers, who also gain access to comprehensive Pro Research Reports covering 1,400+ US equities.

Following these sales, Mr. Privitera directly owns 134,341 shares of AtriCure common stock. The filing noted that these shares were sold pursuant to a 10b5-1 trading plan, which was adopted on February 20, 2026.

In other recent news, AtriCure has reported impressive third-quarter earnings results, surpassing analysts’ expectations. The company achieved earnings per share of $0.17, significantly outperforming the forecasted loss of $0.04 per share. Revenue for the quarter reached $154.5 million, exceeding Wall Street’s estimate of $151.15 million and reflecting a 15% increase from the previous year. BTIG responded to these strong results by raising its price target for AtriCure to $70, maintaining a Buy rating. Revenue growth was driven by robust demand across AtriCure’s cardiac surgery portfolio. Despite these positive financial outcomes, the company’s stock experienced a slight decline in after-hours trading. The revenue reported also surpassed the company’s guidance, which had anticipated a 1% to 2% sequential decline from the second quarter. These developments highlight AtriCure’s strong performance and market position in recent times.

Read the full story at Investing.com · All coverage of this story